[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peyronie-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peyronie-disease":151},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,63,96,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100617336","extracorporeal-shockwave-therapy-in-the-treatment-of-peyronies-disease-100617336",false,"NCT07317297","Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease","Inclusion Criteria:\n\n* Male individuals aged 18-65 years.\n* Having been diagnosed with Peyronie's Disease that has been stable (without increasing pain and curvature) for at least 6 months.\n* Presence of palpable penile plaque.\n\nExclusion Criteria:\n\n* Acute inflammatory stage (painful, progressive)\n* Having previously undergone surgery, needle therapy (e.g., Xiaflex), or Extracorporeal Shockwave Therapy for peyronie's disease.\n* Uncontrolled diabetes, severe coagulopathy, or receiving anticoagulant therapy.\n* History of penile cancer.\n* Severe erectile dysfunction.\n* Patients who are considered unable to comply with the study protocol or who cannot attend follow-up visits.",true,"MALE","18 Years","65 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","Investigation of the effectiveness of extracorporeal shock wave therapy in the treatment of Peyronie's disease.",[27],"Peyronie Disease","RECRUITING","2026-01-15",{"date":31,"type":32},"2026-01-16","ACTUAL",{"date":34,"type":32},"2026-01-10",{"date":36,"type":21},"2026-03-30",{"name":38,"class":39},"Uskudar University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":40},"100521118","concurrent-low-intensity-shockwave-therapy-on-collagenase-clostridium-histolyticum-for-peyronies-disease-100521118","NCT06065436","Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease","Impact of Concurrent Low Intensity Shockwave Therapy on Clinical Outcomes With Collagenase Clostridium Histolyticum in Peyronie's Disease: A Randomized Controlled Trial","Inclusion Criteria\n\n• Diagnosed with PD\n\n* Palpable penile plaque\n* Dorsal, lateral, or dorsolateral penile curvature\n* Penile curvature \\> 30 degrees and \\\u003C 90 degrees as measured using goniometer during objective curvature assessment\n* Non-calcified plaque or grade 1 calcification (\"stippling\", no shadowing) as determined by penile duplex Doppler ultrasound (PDDU)\n* \"Stable PD symptoms' defined as PD symptom duration \\> 6-months or stable symptoms \\> 3-months\n\nExclusion Criteria:\n\n* Prior intralesional injections or surgery for PD.\n* Severe baseline penile pain.\n* Moderate or severe baseline ED based on IIEF-EF domain.\n* History of low intensity shockwave therapy for sexual dysfunction (ED or PD).\n* Ventral (downward) or ventrolateral penile curvature.\n* Moderate or severe (grade 2\u002F3) plaque calcification as determined by PDDU.\n* Inability to achieve satisfactory erection rigidity at time of baseline curvature assessment.",{"count":49,"type":21},60,[24],"The purpose of this research is to determine whether or not low-intensity shockwave therapy (LiSWT) with Xiaflex treatment will result in greater improvements to the curvature of the penis.",[27,53],"Erectile Dysfunction","2026-01-05",{"date":56,"type":32},"2026-01-07",{"date":58,"type":32},"2024-01-19",{"date":60,"type":21},"2027-01",{"name":62,"class":39},"Mayo Clinic",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":40},"100593781","platelet-rich-plasma-injections-from-cord-blood--penile-traction-vs-penile-traction-alone-in-patients-with-peyronies-disease-open-label-single-center-randomized-study-100593781","NCT07010900","Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease. Open-label, Single-center Randomized Study","Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease.","CB-PRP-TRAC1","Inclusion Criteria:\n\n* Patients with Peyronie's Disease (IPP) Penile curvature greater than 30 degrees (autophotography in erection with goniometer measurement) Patients candidates for penile traction Age: 18-75 years Good health conditions Preserved erection (IIEF \\>20) Complete blood count with differential and coagulation within the normal range (platelets between 150,000 and 450,000 μL) HIV, HCV, and HbsAg negative The fertile partner of the patient randomized to the experimental group must use an acceptable highly effective contraceptive method (oral contraceptives, intrauterine device, abstinence, vasectomized partner) for the entire duration of the study Informed consent to the study\n\nExclusion Criteria:\n\nCoagulopathies, platelet disorders Major active infections Previous penile surgery (excluding circumcision and condyloma removal) Previous infiltrative therapy or penile traction treatment","75 Years",{"count":73,"type":21},42,[24],"The goal of this clinical trial is to learn if Platelet-Rich Plasma Injections from Cord Blood (CB-PRP) is useful in Peyronie disease.\n\nThe primary goal is evaluation of patient satisfaction at 1 and 3 months after treatment completion using the PDQ Questionnaire\n\nSecondary Objectives are:\n\n* Measurement of penile curvature measured with a goniometer with spontaneous erection before and after treatment (1 and 3 months)\n* Measurement of penile length in stretching before and after treatment (1 and 3 months)\n* Evaluation of the improvement in quality of life, through the Short-Form Health Survey 12 (SF-12) health status questionnaire and through the Hospital Anxiety and Depression Scale (HADS)\n\nParticipants will be randomized in two groups:\n\n* penile extender alone\n* penile extender + CB PRP injection (1 injection every 15 days - 3 in totalinjections)",[27,77,78,79,80,81],"Penile Curvature","PRP Injection","Cord Blood","Randomised Clinical Trial","Penile Injection Therapy",[83,84,85,86],"penile exteder","peyronie disease","prp","cord blood prp","2025-05-30",{"date":89,"type":32},"2025-06-08",{"date":91,"type":21},"2025-05-28",{"date":93,"type":21},"2026-12-31",{"name":95,"class":39},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":103,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100566004","phase-4-delayed-dose-collagenase-clostridium-histolyticum-cch-protocol-for-men-with-peyronies-disease-100566004","NCT06649539","Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease","Efficacy of a Step-wise Protocol in Optimizing CCH Outcomes in Men With Peyronie's Disease","Inclusion Criteria:\n\n* Men with Peyronie's Disease\n* Older than 18 years old\n* Curvature ≥30 degrees\n* Ability to achieve an erection satisfactory for intercourse with or without phosphodiesterase-5 (PDE5) inhibitors\n* The patient exhibits a palpable plaque consistent with Peyronie's Disease\n* For partners, the only inclusion criteria is being willing to complete a questionnaire\n\nExclusion Criteria:\n\n* Prior surgical treatment on the penis (other than circumcision)\n* Prior treatment with CCH injections\n* Any contraindications to CCH - as determined by the PI","ALL",{"count":105,"type":21},40,[107],"PHASE4","Our team has previously demonstrated efficacy in performing a novel collagenase Clostridium histolyticum (CCH) injection protocol in men who previously failed to achieve a response to an initial 4 series of CCH.\n\nThe objective of the current study is to evaluate a protocol that incorporates limited in-office modeling for up to 4 series, followed by up to 2 additional salvage series to determine safety and efficacy compared to historical data.\n\nParticipants will receive up to 4 series of CCH injections using our previously published protocol, with mild in-office modeling. CCH injections are given on back-to back days, after which they are counseled to utilize Restorex and sildenafil daily, as instructed. Patients will undergo mild in-office modeling on day 2.\n\nThe sexual partners of study participants will also be invited to enroll in the study and will complete non-validated questionnaires detailing their level of support for the patient's treatment.",[27],[111,112,113,114,115,116],"collagenase clostridium histolyticum","curvature","Restorex","Xiaflex","traction","salvage","2025-02-12",{"date":119,"type":32},"2025-02-13",{"date":121,"type":32},"2024-10-11",{"date":123,"type":21},"2029-10",{"name":125,"class":39},"Charitable Union for the Research and Education of Peyronie's Disease",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":40},"100539424","non-ablative-radiofrequency-and-low-intensity-shock-wave-therapy-in-fibrotic-plaque-in-men-with-peyronies-disease-100539424","NCT06303661","Non-ablative Radiofrequency and Low Intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease","Non-ablative Radiofrequency and Low-intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease: Case Series","Inclusion Criteria:\n\n* Clinical complaint related to Peyronie's disease;\n* At any stage of the disease (acute or chronic).\n\nExclusion Criteria:\n\n* Users of a pacemaker, cardiac defibrillator implant or any other electromagnetic implant;\n* Metallic implants over or under the area to be treated.","80 Years",{"count":135,"type":21},10,[24],"The goal of this one arm clinical trial is to evaluate the safety and describe the clinical response of non-ablative radiofrequency treatment associated with shockwave therapy in men with Peyronie's disease. The main question\\[s\\] it aims to answer are: • is the treatment safe? • is there any clinical response to the proposed treatment? Participants will respond to five validated questionnaires: International Index of Erectile Dysfunction (IIEF-5), Medical Outcomes Study 36 - Item Short - Form Health Survey (SF-36), Peyronie's Disease Questionnaire (PDQ), Scale Hospital for Anxiety and Depression (SHAD) and the Erection Quality Questionnaire (EQQ); will undergo a physical assessment that includes palpation of the fibrotic plaque on the penis, pharmacological induction of erection, and assessment of the size of the fibrotic plaque through ultrasound. Every five sessions, the participant's degree of satisfaction will be measured using a 5-point Likert scale, as well as the evolution of symptoms will also be observed, using a 10-point Visual Analogue Scale (VAS) and penile pain, if present. The entire evaluation protocol will be applied before (pre-test), after treatment (post-test) and 1 month after the end of treatment. Volunteers will be monitored by telephone to verify the long-term response after 3, 6, 9 and 12 months of completed treatment in relation to the Likert scale and VAS. The treatments they'll be given are • of monopolar non-ablative radiofrequency associated with • low-intensity shock wave therapy.",[27],[27,140,141],"Non ablative radiofrequency","Low-intensity Shock Waves Therapy","2024-05-27",{"date":144,"type":32},"2024-05-29",{"date":146,"type":32},"2024-01-08",{"date":148,"type":21},"2026-06",{"name":150,"class":39},"Centro de Atenção ao Assoalho Pélvico","Peyronie' Disease"]